RIGL Financial Facts

Contract revenues from collaborations: 3.76M
General and administrative: 4.56M
See Full Income Statement

Other accrued liabilities: 1.04M
Total current liabilities: 20.63M
See Full Balance Sheet

Rigel Pharmaceuticals, Inc. (RIGL) Earnings

  |   Expand Research on RIGL
Next EPS Date 8/4/21 *Est. EPS Growth Rate -100.0% *Last Qtr.
Average EPS % Beat Rate +2.8% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS +0.8% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/5/21 Q121 N/A$0.00 N/A N/A$31.05M N/A N/A N/A
3/2/21 Q420 -$0.11-$0.11 $0.00$18.45M$18.1M N/A Details
11/5/20 Q320 N/A-$0.12 N/A N/A$17.24M N/A N/A N/A
8/4/20 Q220 N/A-$0.13 N/A N/A$13.75M N/A N/A N/A
5/5/20 Q120 $0.13$0.13 $0.00$55.76M$56.71M N/A Details
2/27/20 Q419 -$0.10-$0.08 -$0.02$15.4M$15.66M N/A Details
11/5/19 Q319 -$0.07-$0.11 +$0.04$20.86M$16.38M N/A Details
8/6/19 Q219 -$0.12-$0.14 +$0.02$10.46M$9.28M N/A Details